However, a meta-analysis of studies looking at mTOR inhibitors specifically demonstrated that monotherapy agents such as Temsirolimus were not able to achieve any significant tumor response—though it was able to afford some short-lived tumor control with a PFS of 1.86 months. Here, MTOR is linked to neoplasm.